AlzGene - Gene overview of all published AD-association studies for CLU
Back Search Methods Disclaimer Credits
 Gene: CLU  (CLI; APOJ; TRPM-2; TRPM2; SP-40; SGP-2; SGP2; MGC24903)  Entrez Gene    View on PDGene   View on SZGene
 Protein: clusterin  (apolipoprotein J)  ProteinLink
 Chromosome: 8   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 18 April 2011
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      AD Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Biffi, 2010
Overlaps with
Jun, 2010
CL  1  (detail)  168
(52%)
C-75.5 + 7.7
(-)
215
(55%)
75.9 + 5.5
(-)
n.a.
Carrasquillo, 2010
USA CL  1  (detail)  1829
(-)
M--2576
(-)
-Positive
Corneveaux, 2010
Overlaps with
Jun, 2010
CL  1  (detail)  1019
(64%)
N--591
(48%)
-n.a.
Giedraitis, 2009
Sweden (ULSAM) CL  1  (detail)  86
(0%)
C80.2
(72-85)
-404
(0%)
81.8
(80-84)
Negative
Guerreiro, 2010
Portugal CL  5  (detail)  403
(62%)
C67
(42-86)
70
(-)
435
(-)
-Negative
Guerreiro, 2010
UK CL  4  (detail)  489
(59%)
C54
(21-78)
-632
(-)
-Negative
Harold, 2009
Overlaps with
Lambert, 2009 (Belgium)
CL  1  (detail)  1091
(66%)
M74.4
(-)
78.6
(-)
662
(58%)
63
(-)
n.a.
Harold, 2009
Stage 2 (UK, Ireland) CL  1  (detail)  198
(79%)
C76.2
(-)
81.7
(-)
372
(64%)
76.6
(-)
Positive
Harold, 2009
Stage 2 (UK-ART) CL  1  (detail)  82
(79%)
C73.7
(-)
78
(-)
305
(68%)
74
(-)
Positive
Harold, 2009
Stage 2 (Germany) CL  1  (detail)  248
(65%)
C69.4
(-)
75.7
(-)
618
(66%)
79.6
(-)
Positive
Harold, 2009
Stage 2 (Greece) CL  1  (detail)  404
(65%)
C69
(-)
76.7
(-)
383
(38%)
54.9
(-)
Positive
Harold, 2009
Stage 1 (USA) CL,PO  1  (detail)  1159
(58%)
M73.5
(-)
80.7
(-)
1783
(56%)
68.1
(-)
Positive
Harold, 2009
Stage 1 (Germany) CL,PO  1  (detail)  555
(64%)
C70.5
(-)
72.9
(-)
824
(51%)
56.5
(-)
Positive
Harold, 2009
Stage 1 (UK, Ireland) CL,PO  1  (detail)  2227
(65%)
M72.9
(-)
79.7
(-)
5241
(53%)
51.2
(-)
Positive
Hu, 2011
* Recently Added *
USA (Pfizer-GWAS) CL  1  (detail)  733
(-)
C--792
(-)
-Positive
Hu, 2011
* Recently Added *
Overlaps with
Naj, 2011 (GenADA)
CL  1  (detail)  798
(-)
C--776
(-)
-n.a.
Hu, 2011
* Recently Added *
Overlaps with
Naj, 2011 (ADNI)
CL  1  (detail)  300
(-)
C--196
(-)
-n.a.
Jun, 2010
USA (ADGC-C) CL  5  (detail)  5935
(-)
M--7034
(-)
-Positive
Jun, 2010
Israel (ADGC-Wadi Ara) CL  3  (detail)  124
(-)
M--142
(-)
-Negative
Kamboh, 2010
Overlaps with
Naj, 2011
CL  3  (detail)  1348
(66%)
M72.6 + 6.4
(-)
-1359
(61%)
74.7 + 6.5
(-)
n.a.
Lambert, 2009
Stage 2 (Belgium) CL  3  (detail)  1084
(66%)
C74.4 + 8.6
(-)
78.6 + 8.1
(-)
509
(58%)
67 + 12.9
(-)
Positive
Lambert, 2009
Stage 2 (Finland) CL  3  (detail)  619
(67%)
C71.4 + 7.5
(-)
71.4 + 7.5
(-)
664
(60%)
69.2 + 6
(-)
Positive
Lambert, 2009
Stage 2 (Italy) CL  3  (detail)  1520
(68%)
C73.8 + 8.8
(-)
76.6 + 8.7
(-)
1291
(55%)
72.3 + 8.9
(-)
Positive
Lambert, 2009
Stage 2 (Spain) CL  3  (detail)  755
(57%)
C72.5 + 9.4
(-)
75.3 + 9.3
(-)
833
(62%)
76.9 + 10.9
(-)
Negative
Lambert, 2009
Stage 1 (France) CL  3  (detail)  2025
(66%)
C68.3 + 9
(-)
73.7 + 8.9
(-)
5328
(61%)
73.8 + 5.4
(-)
Positive
Naj, 2011
* Recently Added *
USA (ADGC-GWAS) CL  1  (detail)  8309
(61%)
M--7366
(58%)
-Positive
Naj, 2011
* Recently Added *
USA (ADGC-REP) CL  1  (detail)  3531
(60%)
M--3565
(61%)
-Positive
Seshadri, 2010
Europe (CHARGE; GWAS) CL  1  (detail)  1367
(-)
M--20866
(-)
-Negative
Seshadri, 2010
Overlaps with
Naj, 2011
CL  1  (detail)  829
(52%)
M-80 + 10
(-)
536
(63%)
80 + 7
(-)
n.a.
Seshadri, 2010
Overlaps with
Harold, 2009 (GERAD1; Stage 1)
CL  1  (detail)  810
(57%)
M-73 + 4
(-)
1202
(50%)
74 + 5
(-)
n.a.
Seshadri, 2010
Overlaps with
Lambert, 2009 (EADI1; Stage2)
CL  1  (detail)  2025
(66%)
C68.3 + 9
(-)
73.7 + 8.9
(-)
5328
(61%)
73.8 + 5.4
(-)
n.a.
Seshadri, 2010
Overlaps with
Harold, 2009 (GERAD1; Stage 3)
CL  1  (detail)  3333
(-)
M--6995
(-)
-n.a.
Seshadri, 2010
Spain (ACE) CL  1  (detail)  1140
(70%)
C-78.8 + 7.9
(-)
1209
(53%)
49.9 + 9.2
(-)
Positive
Tycko, 1996
USA    2  (detail)  53
(-)
U-70 + 10.5
(-)
43
(-)
74 + 8.6
(-)
Negative
 African Descent
Jun, 2010
USA (ADGC-AA) CL  5  (detail)  462
(-)
M--449
(-)
-Negative
Tycko, 1996
USA (I)    2  (detail)  165
(-)
U-78 + 7.4
(-)
273
(-)
73 + 5.8
(-)
Negative
Tycko, 1996
USA (II)    2  (detail)  32
(-)
U-79 + 5.9
(-)
49
(-)
83 + 9
(-)
Negative
 Asian
Yu, 2010a
China CL  3  (detail)  324
(56%)
C-76.8 + 5.5
(-)
388
(54%)
75.9 + 4.6
(-)
Positive
 Hispanic
Jun, 2010
USA (ADGC-H) CL  2  (detail)  549
(-)
M--544
(-)
-Negative
Lee, 2011
* Recently Added *
Overlaps with
Jun 2010 (ADGC-H)
CL,PO  4  (detail)  549
(-)
C79.9 + 8
(-)
-544
(-)
78.8 + 6.4
(-)
Positive
Tycko, 1996
USA    2  (detail)  126
(-)
U-77 + 8.2
(-)
179
(-)
73 + 6.1
(-)
Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds    
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Wijsman, 2011
* Recently Added *
Overlaps with
Naj, 2011
 2  (detail)  6111848
(-)
M--1991
(-)
-n.a.
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine AD diagnosis ->  "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-) :  Either no data provided or in case of overlap, data included in original study.
AlzGene Recent Updates
AlzGene Top Results
AlzGene Stats
Studies: 1395
Genes: 695
Polymorphisms: 2973
Meta-analyses: 320
Cure Alzheimer's Fund
Proud supporter of the AlzGene database.
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.

NCRAD

The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.